Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04674358 · ClinicalTrials.gov registry record · Phase 2
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 329
- Enrollment target
NCT04674358 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 329 participants.
The verdict
NCT04674358, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 329 participants
- Enrollment target
Study Summary
The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease.
Interventions
- DRUG Reproxalap Ophthalmic Solution (0.25%)
- DRUG Vehicle Opthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2020-11-21 |
| Est. Completion | 2021-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04674358
The ClinicalTrials.gov registry entry for NCT04674358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Reproxalap Ophthalmic Solution (0.25%) is the first listed.
NCT04674358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04674358 about?
NCT04674358 is a clinical study titled "The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease". The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease.
What is the current status of trial NCT04674358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 329 participants. The study started on 2020-11-21. Estimated completion is 2021-09-12.
What interventions are being tested in trial NCT04674358?
The interventions under investigation include: Reproxalap Ophthalmic Solution (0.25%) (DRUG), Vehicle Opthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04674358?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.